Loading
In 260 gallbladder cancer patients from New York and Santiago, HER2 gene changes were found in about one in seven at both centres, split between extra copies and point mutations, and patients with them lived longer.
260 patients with gallbladder cancer, 237 from Memorial Sloan Kettering and 23 from the Pontificia Universidad Catolica de Chile, were profiled with MSK-IMPACT. Clinical characteristics did not differ except gallstone prevalence, which was higher in Chile (85% versus 44%; P = 0.0003). The prevalence of ERBB2 alterations was comparable (15% versus 9%; P = 0.42).
Overall, ERBB2 alterations were present in 14% of patients: 8% amplification, 4% mutation, 1.5% concurrent amplification and mutation, and 0.4% fusion. Patients whose tumours harboured ERBB2 alterations had better overall survival than ERBB2 wild-type patients (22.3 versus 11.8 months; P = 0.024).
The cleanest split of HER2 alterations in gallbladder cancer into amplification and mutation, which matters because IHC and ISH only see the amplified tumours. It also shows the high-incidence Chilean population has not been sequenced at scale.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2, Gallbladder cancer.
Shares Zanidatamab, Trastuzumab deruxtecan, HER2, Gallbladder cancer.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2 ISH amplified (ERBB2 gene amplification), Zanidatamab, HER2.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2 ISH amplified (ERBB2 gene amplification), Zanidatamab, HER2.
Shares Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, HER2, Gallbladder cancer.
Shares HER2 (ERBB2) activating mutation, HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2, Gallbladder cancer.
Shares Memorial Sloan Kettering Cancer Center, Trastuzumab deruxtecan, HER2.
Shares Ghassan K. Abou-Alfa, HER2, Gallbladder cancer.